Director Lucas Svetlana buys 20,000 shares of JSPR at $2.43 amid 3-insider cluster; stock down 90.6% from 52-week high of $24.73
Lucas Svetlana, a director, purchased 20,000 shares at $2.43 on 2025-09-22, establishing a new position worth $48,600.00. This transaction is part of a cluster pattern with 3 other insiders buying within the past 14 days. The stock is trading at a severe discount to its 52-week high of $24.73 (currently $2.33, down 90.6%), having declined 59.0% over 90 days and 21.3% over 30 days. Jasper Therapeutics reported a net loss of $26.7M in its most recent fiscal year with a market cap of $37.9M, indicating material unprofitability. The convergence of multiple insider purchases at depressed valuations alongside pronounced losses and significant downward price momentum warrants close examination of the company's operational trajectory and near-term catalysts.